Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide in Obese Subjects Without Diabetes
NCT02075281Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Jan 2015
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efpeglenatide in obesity, sponsored by Hanmi Pharmaceutical. Started Feb 2014; status: completed.
02
Drugs
efpeglenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02075281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075281.